PMID- 34580638
OWN - NLM
STAT- MEDLINE
DCOM- 20220112
LR  - 20220427
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2021
DP  - 2021
TI  - Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 
      2 Diabetes Mellitus: A 52-Week Clinical Study.
PG  - 3361309
LID - 10.1155/2021/3361309 [doi]
LID - 3361309
AB  - INTRODUCTION: Hypoglycemic drugs affect the bone quality and the risk of 
      fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to 
      investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) 
      and insulin on bone mineral density (BMD) in T2DM. METHODS: In this 
      single-blinded study, a total of 65 patients with T2DM were randomly assigned 
      into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n 
      = 19), insulin glargine group (n = 10), and placebo (n = 17). General clinical 
      data were collected, and BMD was measured by dual-energy X-ray absorptiometry. 
      RESULTS: Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased 
      significantly in the exenatide (8.11 +/- 0.24% vs. 7.40 +/- 0.16%, P = 0.007), 
      dulaglutide (8.77 +/- 0.37% vs. 7.06 +/- 0.28%, P < 0.001), and insulin glargine 
      (8.57 +/- 0.24% vs. 7.23 +/- 0.25%, P < 0.001) groups after treatment. In the 
      exenatide group, the BMD of the total hip increased. In the dulaglutide group, 
      only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of 
      decrease was less than that in the placebo group; the BMD of L1-L4, femoral neck, 
      and total hip decreased significantly (P < 0.05) in the placebo group, while in 
      the insulin glargine group, the BMD of L2, L4, and L1-4 increased (P < 0.05). 
      Compared with the placebo group, the BMD of the femoral neck and total hip in the 
      exenatide group and the insulin glargine group were increased significantly (P < 
      0.05); compared with the exenatide group, the BMD of L4 in the insulin glargine 
      group was also increased (P = 0.001). CONCLUSIONS: Compared with the placebo, 
      GLP-1RAs demonstrated an increase of BMD at multiple sites of the body after 
      treatment, which may not exacerbate the consequences of bone fragility. 
      Therefore, GLP-1RAs might be considered for patients with T2DM. This trial is 
      registered with ClinicalTrials.gov NCT01648582.
CI  - Copyright (c) 2021 Ting-ting Cai et al.
FAU - Cai, Ting-Ting
AU  - Cai TT
AUID- ORCID: 0000-0001-5075-9734
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
FAU - Li, Hui-Qin
AU  - Li HQ
AUID- ORCID: 0000-0002-6319-1196
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
FAU - Jiang, Lan-Lan
AU  - Jiang LL
AUID- ORCID: 0000-0002-7626-1501
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
FAU - Wang, Hui-Ying
AU  - Wang HY
AUID- ORCID: 0000-0003-1835-5873
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
FAU - Luo, Meng-Hui
AU  - Luo MH
AUID- ORCID: 0000-0002-3358-305X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
FAU - Su, Xiao-Fei
AU  - Su XF
AUID- ORCID: 0000-0002-5567-8244
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
FAU - Ma, Jian-Hua
AU  - Ma JH
AUID- ORCID: 0000-0001-9383-2559
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Jiangsu, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT01648582
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210917
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 9P1872D4OL (Exenatide)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - *Bone Density
MH  - Diabetes Mellitus, Type 2/*drug therapy/*physiopathology
MH  - Exenatide/pharmacology/therapeutic use
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glucagon-Like Peptides/analogs & derivatives/pharmacology/therapeutic use
MH  - Humans
MH  - Immunoglobulin Fc Fragments/pharmacology/therapeutic use
MH  - Insulin Glargine/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/pharmacology/therapeutic use
PMC - PMC8464416
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/29 06:00
MHDA- 2022/01/13 06:00
PMCR- 2021/09/17
CRDT- 2021/09/28 06:42
PHST- 2021/05/18 00:00 [received]
PHST- 2021/07/22 00:00 [revised]
PHST- 2021/09/03 00:00 [accepted]
PHST- 2021/09/28 06:42 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2022/01/13 06:00 [medline]
PHST- 2021/09/17 00:00 [pmc-release]
AID - 10.1155/2021/3361309 [doi]
PST - epublish
SO  - Biomed Res Int. 2021 Sep 17;2021:3361309. doi: 10.1155/2021/3361309. eCollection 
      2021.